Medical management of menorrhagia

O'Leary, A. J.; Tejura, H.

doi:10.1016/j.rigp.2005.06.003

Cited by 1 publication

(3 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Small studies have shown that they induce amenorrhoea in more than 90% of women (49,50), and improve irregular bleeding and premenstrual symptoms. Small studies have shown that they induce amenorrhoea in more than 90% of women (49,50), and improve irregular bleeding and premenstrual symptoms.…”

Section: Combined Oral Contraceptivesmentioning

confidence: 99%

“…It is generally recommended that it should not be used for more than 3 months at a time and is therefore not considered as a first line treatment for DUB (49). It inhibits the mid-cycle FSH and LH surge and steroidogenesis in the corpus luteum, resulting in suppression of the endometrium.…”

Section: Combined Oral Contraceptivesmentioning

confidence: 99%

“…Hormone replacement therapy Finally, hormone replacement therapy can be helpful to regulate menstrual bleeding in perimenopausal women, although it does not markedly reduce blood loss (49).…”

Section: Combined Oral Contraceptivesmentioning

confidence: 99%

See 2 more Smart Citations

Dysfunctional uterine bleeding: from adolescence to menopause

Druckmann¹

2010

Hormone Molecular Biology and Clinical Investigation

View full text Add to dashboard Cite

Dysfunctional uterine bleeding (DUB) is defined as excessive or prolonged uterine bleeding in premenopausal women that is not caused by pelvic pathology, medications, systemic disease or pregnancy. It is a common condition that can lead not only to physical symptoms such as iron deficiency, anaemia, cramps and fatigue, but also has significant psychological and social effects that impair a woman's quality of life. Progesterone is highly important in the regulation of menstrual bleeding and a progesterone-deficient anovulatory state is a common cause of DUB. There are a wide range of treatment options available including hormonal therapies (oral cyclical progestogens, depot progestogens, progestogen-releasing intrauterine devices, combined oral contraceptives, danazol, gonadotrophin-releasing hormone analogues and hormone replacement therapy), non-hormonal therapies (non-steroidal anti-inflammatory drugs and antifibrinolytic drugs) and surgery (hysterectomy and endometrial ablation). The choice of appropriate therapy should be based on factors such as the mechanism behind the DUB, which symptoms are most problematic, and the woman's need for fertility or contraception. However, there is currently a lack of clinical evidence to help support these decisions.

show abstract